PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus in poor-risk diffuse large B-cell lymphoma (DLBCL).
Tongyu Lin
No relevant relationships to disclose
Jun Zhu
No relevant relationships to disclose
Kamal Bouabdallah
No relevant relationships to disclose
Michinori Ogura
No relevant relationships to disclose
Masayuki Hino
No relevant relationships to disclose
Jin Seok Kim
No relevant relationships to disclose
Cassandra Wu
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Claudia Corrado
Employment or Leadership Position - Novartis
Thomas E. Witzig
Consultant or Advisory Role - Celgene; Novartis; Seattle Genetics; Takeda
Honoraria - Avila Therapeutics; Hospira
Research Funding - Novartis